| Date Filed | Type | Description |
| 03/25/2021 |
GN
| Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights |
| 03/01/2021 |
GN
| Satsuma Pharmaceuticals Announces Updated STS101 Development Plan |
| 11/24/2020 |
GN
| Satsuma Pharmaceuticals to Participate in the Evercore ISI 3rd Annual HealthCONx Conference |
| 11/02/2020 |
GN
| Satsuma Pharmaceuticals to to participate in the following November Virtual Investor Conferences |
| 09/03/2020 |
GN
| Satsuma Pharmaceuticals to Participate in September Virtual Investor Conferences |
| 08/12/2020 |
GN
| Satsuma Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results |
| 07/07/2020 |
GN
| Satsuma Pharmaceuticals Announces the Appointment of Thomas M. Soloway to its Board of Directors |
| 06/11/2020 |
GN
| Satsuma Pharmaceuticals to Present Two Posters at the American Headache Society's Annual Scientific Meeting Hosted via a Virtual Meeting Platform |
| 06/01/2020 |
GN
| Satsuma Completes Enrollment in Pivotal Phase 3 EMERGE trial of STS101 for Acute Treatment of Migraine |
| 05/27/2020 |
GN
| Satsuma Pharmaceuticals to To Present at the Jefferies Virtual Healthcare Conference |
| 05/18/2020 |
GN
| Satsuma Pharmaceuticals Announces Poster Presentations on the American Academy of Neurology 2020 Science Highlights Virtual Platform |
| 05/12/2020 |
GN
| Satsuma Pharmaceuticals Reports First Quarter 2020 Financial and Business Results |
| 03/10/2020 |
GN
| Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Results |
| 03/05/2020 |
GN
| Satsuma Pharmaceuticals Appoints Rob Janosky as Chief Commercial Officer |
| 02/18/2020 |
GN
| Satsuma Pharmaceuticals to Present at the 9th Annual SVB Leerink Global Healthcare Conference |
| 01/28/2020 |
GN
| Satsuma Pharmaceuticals Announces Publication of STS101 Phase 1 Clinical Trial Results in HEADACHE: The Journal of Head and Face Pain |
| 11/26/2019 |
GN
| Satsuma Pharmaceuticals to Present at the 2nd Annual Evercore ISI HealthCONx Conference |
| 11/12/2019 |
GN
| Satsuma Pharmaceuticals Reports Third Quarter 2019 Financial and Business Results |
| 04/22/2014 |
SC 13D/A
| THL Equity Advisors VI, LLC reports a 0% stake in STERLING FINANCIAL CORPORATION |
| 04/22/2014 |
SC 13D/A
| Warburg Pincus Private Equity X, L.P. reports a 0% stake in STERLING FINANCIAL CORPORATION |
| 04/18/2014 |
8-K
| Quarterly results |
| 04/17/2014 |
10-K/A
| Annual Report for the period ended December 31, 2013 [amend] |
| 04/10/2014 |
8-K
| Temporary Suspension of Trading Under Registrant's Employee Benefit Plans, Other Events, Financial Statements and Exhibits |
| 04/10/2014 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 04/01/2014 |
8-K
| Other Events, Financial Statements and Exhibits |
| 03/19/2014 |
8-K
| Other Events, Financial Statements and Exhibits |
| 02/26/2014 |
10-K
| Annual Report for the period ended December 31, 2013 |
| 02/26/2014 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits |
| 02/19/2014 |
8-K
| Other Events |
| 02/14/2014 |
SC 13G/A
| WELLINGTON MANAGEMENT GROUP LLP reports a 0% stake in Sterling Financial Corporation |
| 01/30/2014 |
8-K
| Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits |
| 01/22/2014 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition: |
| 11/06/2013 |
10-Q
| Quarterly Report for the period ended September 30, 2013 |
| 10/28/2013 |
425
| Form 425 - Prospectuses and communications, business combinations |
|